阿替普酶与艾地苯醌联合用药对ACI病人恢复情况及神经损伤指标和TXB2水平的影响

目的研究阿替普酶与艾地苯醌联合用药对急性脑梗死（ACI）病人恢复情况和神经损伤指标及血栓素B2（TXB2）水平的影响。方法选取ACI病人120例作为研究对象，随机分为观察组和对照组，各60例。观察组病人采用阿替普酶和艾地苯醌联合治疗，对照组病人采用阿替普酶治疗，2组病人均治疗2周。比较2组病人的疗效和神经功能、预后、凝血功能及TXB2水平。结果观察组病人治疗总有效率为83.33%（50/60），明显高于对照组的55.00%（33/60）（P < 0.01）。2组病人治疗前的神经功能缺损评分（CSS）、美国国立卫生研究院卒中量表（NIHSS）评分和Barthel指数差异均无统计学意义（P>0.05），治疗后观察组CSS、NIHSS评分均明显低于对照组，Barthel指数明显高于对照组（P < 0.01）。观察组病人中改良Rankin量表评分>2分例数明显低于对照组（P < 0.01）。2组治疗前D-二聚体、TXB2和凝血酶时间、凝血酶原时间、活化部分凝血活酶时间差异均无统计学意义（P>0.05），治疗后观察组D-二聚体、TXB2均明显低于对照组（P < 0.01），凝血酶时间、凝血酶原时间、活化部分凝血活酶时间水平均高于对照组（P < 0.05~P < 0.01）。结论阿替普酶与艾地苯醌联合用药治疗ACI，病人的神经功能得到较好恢复，血液凝血指标及TXB2含量明显改善，值得临床推广。

Study on the effects of ateplase combined with adebenquinone on the recovery,index of nerve injury and TXB2 level in patients with ACI

ObjectiveTo study the effects of ateplase combined with adebenquinone on the recovery, nerve injury index and TXB2 level in acute cerebral infarction(ACI) patients.MethodsOne hundred and twenty patients with ACI were randomly divided into the observation group and control group(60 cases in each group).The observation group was treated with the ateprase combined with edebenzoquinone, while the control group was treated with ateprase for 2 weeks.The therapeutic effects, nerve function, prognosis, coagulation function and TXB2 level were compared between two groups.ResultsThe total effective rate in observation group(83.33%) was significantly higher than that in control group(55.00%) (P < 0.01).The differences of the CSS score, NIHSS score and Barthel index between two groups before treatment were not statistically significant(P>0.05).After treatment, the CSS score and NIHSS score in observation group were significantly lower than those in control group, and the Barthel index in observation group was significantly higher than that in control group(P < 0.01).The number of patients with modified Rankin scale score >2 points in observation group was significantly lower than that in control group(P < 0.01).There was no statistical significance in the D-dimer, TXB2 and thrombin time, prothrombin time and ctivated partial thrombin time between two groups before treatment(P>0.05).After treatment, the levels of D-dimer and TXB2 in observation group were significantly lower than those in control group(P < 0.01), and the levels of thrombin time, prothrombin time and activated partial thrombin time in observation group were higher than those in control group(P < 0.05 to P < 0.01).ConclusionsThe combination of alteplase and edibenzoquinone in the treatment of ACI can better recover the patient's neurological function, improve the blood coagulation index and TXB2 level, and is worthy of clinical promotion.